Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > they should give us details re milestones for funding AND
View:
Post by edrose on Jun 11, 2020 12:25pm

they should give us details re milestones for funding AND

THEY SAY KLY AS TO PAY SALZMAN 29 MILLION AND SEPERATE 5 MILLION RE MILESTONES    THIS IS ON TOP OF GIVING SALZMAN 49% OF KLY TO SALZMAN


IR PERSON AS WELL AS CEO AND BOARD WILL ONCE AGAIN NOT RELEASE THIS INFORMATION AND ASK US TO VOTE BLINDLY 

WHAT % OF SALES WILL GO TO KLY VERSUS SALZMAN      I BET KLY WILL ONLY GET VERY SMALL % OF REVENUES
Comment by BrianCano444 on Jun 11, 2020 1:13pm
This post has been removed in accordance with Community Policy
Claritas Pharmaceuticals Inc